Top Markets
Coin of the day
Energenesis Biomedical CO.,LTD. Energenesis Biomedical CO.,LTD.

Energenesis Biomedical CO.,LTD.

6657
株式のランク #22642
Energenesis Biomedical CO.,LTD., a firm established in 2012 and headquartered... Energenesis Biomedical CO.,LTD., a firm established in 2012 and headquartered in Taipei, Taiwan, is an active participant in the biomedicine sector. The company specializes in the development of a diverse range of medical solutions and research materials. Its primary pharmaceutical pipeline includes ENERGI-F703, which is currently undergoing Phase II clinical trials for the treatment of diabetic foot ulcers, and ENERGI-F701, a topical solution for addressing alopecia that is also in its second phase of clinical assessment. The comprehensive portfolio of therapeutic agents further encompasses: ENERGI-F711, formulated as a cream for burns. ENERGI-F702, designed to combat metabolic diseases. ENERGI-F704, targeting inflammatory bowel disease. ENERGI-F708, for the management of asthma. ENERGI-F705, aimed at controlling Parkinson's disease. ENERGI-F707, addressing mitochondrial deficiencies. ENERGI-F706, used to treat cachexia. ENERGI-F709, which serves as a vaccine adjuvant. ENERGI-F710, intended for the regulation of blood phosphate levels. Beyond its therapeutic developments, Energenesis Biomedical also provides a selection of scientific research products, including reagents for Western blotting, cell culture supplements, components for protein isolation and quantification, various laboratory dyes, and buffer solutions.
株価
$0.97305026
最終同期: 2026-08-21
時価総額
$85.54M
変化(1日)
1.16%
変化(1年)
-50.40%
TW
取引 Energenesis Biomedical CO.,LTD. (6657)

カテゴリー

Energenesis Biomedical CO.,LTD.(6657)の配当利回りの履歴
Energenesis Biomedical CO.,LTD.(銘柄コード: 6657)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Energenesis Biomedical CO.,LTD.(6657)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)